FURTHER VALIDATION OF THE MIGRAINE TREATMENT SATISFACTION MEASURE

Author(s)

Martin ML1, Patrick DL2, Bushnell DM1, Gandra SR1, Pesa J31 Health Research Associates, Mountlake Terrace, WA, USA; 2 University of Washington, Seattle, WA, USA; 3 AstraZeneca LP, Wilmington, DE, USA

OBJECTIVE: Initial development of a new measure for assessing patient satisfaction with treatment for migraine headaches utilizes a four-part conceptual model incorporating patient expectations and preferences with self-reported outcomes and satisfaction. In this report we evaluate the psychometric performance of the Migraine Treatment Satisfaction measure (MTS) using participants from a randomized controlled trial of headache management. METHODS: Enrolled migraineurs completed the first two modules of the MTS upon enrollment in the treatment program and the final two modules at six-months. Internal consistency reliability was computed within each of the four modules. Discriminant validity was ascertained by comparison with the Migraine Disability Assessment Questionnaire (MIDAS), Patient Health Questionnaire (PHQ-9), and Migraine Symptom Frequency and Bothersomeness (MSFB) scores. For convergent validity, Pearson's correlation was used to measure associations between MTS scores, general health status (SF-36), MIDAS and MSFB. RESULTS: Overall, 124 migraineurs (mean age 45.4 years, 75% women, 54.1% Caucasian) were enrolled. Internal consistency statistics for the expectations, outcomes, importance ratings, and satisfaction measures were within acceptable ranges (0.83, 0.86, 0.85, and 0.95, respectively) and were consistent with earlier development work for this measure. Satisfaction (MTS) decreased significantly as depression (PHQ-9 scores) increased. MTS scores by symptom bothersomeness tertiles and symptom frequency tertiles showed a significant decrease in satisfaction among those experiencing moderate-severe symptom bothersomeness and symptom frequency. Derived MTS scores showed strong associations with MSFB scores (-0.301; p<0.01), MIDAS (-0.267; p<0.01), general health (0.253; p<0.05), mental health (0.217; p<0.05) and vitality subscales of SF-36 (0.214; p<0.05). Patients on triptans reported a significantly higher satisfaction compared to patients on analgesics (39.5 vs. 32.9; p<0.05). CONCLUSION: MTS can be considered as a valuable instrument to be used for the description of migraine treatment satisfaction.

Conference/Value in Health Info

2005-05, ISPOR 2005, Washington, DC, USA

Value in Health, Vol. 8, No. 3 (May/June 2005)

Code

PNL15

Topic

Patient-Centered Research

Topic Subcategory

Stated Preference & Patient Satisfaction

Disease

Neurological Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×